In summary, this study demonstrated a strategy to optimize conventional network pharmacology, and then explained that the molecular mechanism of CKI treating PC was closely associated with 5 core genes (including CDK1, JAK1, EGFR, MAPK1 and MAPK3), which were related to important signalling pathways (including cell cycle, JAK/STAT and ErbB pathway) and survival-correlated genes (including TSPOAP1, ADGRG6, GPR87, FAM111B and MMP28). This evidence concerns the gene MAPK3 and pachyonychia congenita.